Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myeloid 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Bronchiolitis Obliterans Syndrome 2Malignant Solid Tumors 1Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Burkitt Lymphoma 1Brain Neoplasms 1Blast Crisis 1

Interventions

ibrutinib 5ruxolitinib 3Sirolimus 3Mycophenolic Acid 3fludarabine 2asciminib 2Filgrastim 2Cyclophosphamide 2posaconazole 1pegfilgrastim 1montelukast 1axatilimab 1Whole-Body Irradiation 1Voriconazole 1Tomography, X-Ray Computed 1Specimen Handling 1Saline Solution 1Rituximab 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Panobinostat 1Methotrexate 1Mesna 1Infliximab 1Imatinib Mesylate 1Everolimus 1Erythropoietin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × asciminib × 1 year × Clear all
NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06427811 2026-04-17

ASC4INDIA

Novartis

Phase 4 Completed
85 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡